Page last updated: 2024-11-13

alx40 4c

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

N-alpha-acetyl-nona-D-arginine amide acetate: inhibits HIV-1 by acting as competitive inhibitor of HIV Tat protein; cxcr4 receptor antagonist; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID25077385
SCHEMBL ID16045801
MeSH IDM0248634

Synonyms (15)

Synonym
gtpl607
n-alpha-acetyl-nona-d-arginine amide acetate
alx 40-4c
n-acetyl-d-arginyl-d-arginyl-d-arginyl-d-arginyl-d-arginyl-d-arginyl-d-arginyl-d-arginyl-d-argininamide , acetate salt
alx40-4c
(2r)-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-acetamido-5-guanidino-pentanoyl]amino]-5-guanidino-pentanoyl]amino]-5-guanidino-pentanoyl]amino]-5-guanidino-pentanoyl]amino]-5-guanidino-pentanoyl]amino]-5-guanidino-pentanoyl
ac-(d-arg)9-nh2
153127-49-2
alx-40-4c
alx40 4c
SCHEMBL16045801
DTXSID30165232
HY-P7061
CS-0024689
Q27074420
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID1346821Human CXCR4 (Chemokine receptors)2002The Journal of biological chemistry, Jul-05, Volume: 277, Issue:27
A point mutation that confers constitutive activity to CXCR4 reveals that T140 is an inverse agonist and that AMD3100 and ALX40-4C are weak partial agonists.
AID1346467Human apelin receptor (Apelin receptor)2003Virology, Mar-01, Volume: 307, Issue:1
Cell-cell fusion and internalization of the CNS-based, HIV-1 co-receptor, APJ.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (13)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's6 (46.15)18.2507
2000's7 (53.85)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (7.69%)5.53%
Reviews1 (7.69%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (84.62%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]